Publication
Abstract
Realization of a part of clinical trial called multicentre, randomized phase II study comparing the combination of trastuzumab and capecitabine administered with or without Pertuzumab in patients with HER2-positive metastatic breast cancer whose disease has progressed after one line trastuzumab-based therapy in the treatment of metastatic disability (PHEREXA)